We identified the mouse Lau-PTEN-PDZ as the right candidate for further development as a minimally invasive medicine for self-administration via the nasal, intramuscular, or subcutaneous routes in order to prevent or delay memory defects in the early phases of AD. This evidence concerns the gene PTEN and Alzheimer disease.